Equities

Arcutis Biotherapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ARQT:NSQ

Arcutis Biotherapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)26.61
  • Today's Change0.75 / 2.90%
  • Shares traded1.18m
  • 1 Year change+108.22%
  • Beta1.6758
Data delayed at least 15 minutes, as of Feb 17 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments228272410
Total Receivables, Net73268.46
Total Inventory15137.51
Prepaid expenses201911
Other current assets, total0.620.931.23
Total current assets336330437
Property, plant & equipment, net2.993.904.60
Goodwill, net------
Intangibles, net9.486.447.19
Long term investments------
Note receivable - long term------
Other long term assets0.600.600.08
Total assets349341449
LIABILITIES
Accounts payable14128.83
Accrued expenses673529
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total------
Total current liabilities814738
Total long term debt107202198
Total debt107202198
Deferred income tax------
Minority interest------
Other liabilities, total3.134.234.12
Total liabilities191253240
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital1,2791,071930
Retained earnings (accumulated deficit)(1122)(982)(720)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.01)0.00(1.09)
Total equity15889210
Total liabilities & shareholders' equity349341449
Total common shares outstanding1189761
Treasury shares - common primary issue000.02
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.